Verastem Inc VSTM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
-
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
-
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
-
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
-
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
-
Verastem Oncology to Participate in Upcoming September Investor Conferences
-
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
-
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
Trading Information
- Previous Close Price
- $7.90
- Day Range
- $7.52–8.02
- 52-Week Range
- $3.43–10.82
- Bid/Ask
- $7.63 / $7.95
- Shares Outstanding
- 90.56M
- Market Cap
- $697.34M
- Volume/Avg
- 4M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.81
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 102
- Website
- https://www.verastem.com
Valuation
|
Metric
|
VSTM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 13.94 |
Price/Sales | 7.81 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VSTM
|
|---|---|
Quick Ratio | 2.12 |
Current Ratio | 2.25 |
Interest Coverage | −138.86 |
Quick Ratio
VSTM
Profitability
|
Metric
|
VSTM
|
|---|---|
Return on Assets (Normalized) | −74.46% |
Return on Equity (Normalized) | −374.59% |
Return on Invested Capital (Normalized) | −125.00% |
Return on Assets
VSTM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<dQl#S | LOCK|&Yx$ | $128B | |||
| Moderna Inc
MRNA
| LOCK|Mwj$<qx | LOCK|qb | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%YPVP>& | LOCK|><t$L | $76B | |||
| argenx SE ADR
ARGX
| LOCK|#^?ZKm% | LOCK|Y#g | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|lRV>BM | LOCK|&y? | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|X^wrGt | LOCK|%@#p? | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|f<?n???< | LOCK|W@c% | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|yVlKQl< | LOCK|R< | $24B | |||
| Incyte Corp
INCY
| LOCK|?@PQ#$V | LOCK|x^ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|x!z<&> | LOCK|Tq! | $15B |
United States